STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3956 by analyst upside · 2026-06-27
XOMA
XOMA Royalty Corporation
Healthcare · Market Cap $745M · P/E 26.8x
ANALYST PRICE TARGET
-7.5%
implied upside to consensus target
Current Price $42.15
Consensus Target $39.0
Bull Target $39.0
Bear Target $39.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $22.29
52-Week High $42.81
YTD Return +50.6%
FUNDAMENTALS
Market Cap $745M
P/E Ratio (TTM) 26.8x
Forward P/E 19.7x
EPS (TTM) $1.57
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $49M
Profit Margin 69.6%
52-WEEK RANGE
52-Week Low $22.29
52-Week High $42.81
Current Price $42.15
Bear Target $39.0
Bull Target $39.0
● Now $42.15 ● Target $39.0
TRADING DATA
Avg Volume 213K
YTD Return +50.6%
Analyst Count 1
Consensus Buy
Upside to Target -7.5%
Last Updated 2026-06-27

ANALYST SUMMARY

XOMA Royalty Corporation (XOMA) is currently trading at $42.15 with a Wall Street consensus price target of $39.0, which is 7.5% below the current price over the next 12 months. 1 analysts currently cover XOMA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $39.0, while the most cautious has a target of $39.0.

XOMA operates in the Healthcare sector with a market capitalisation of $745M. The stock is up 50.6% year-to-date and is currently trading near the upper end of its 52-week range of $22.29 – $42.81.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for XOMA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-04-30 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-20 31% win rate (48 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2026-02-24 29% win rate (7 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-12-11 31% win rate (48 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2025-12-11 29% win rate (7 calls)
LUCID CAPITAL MARKETS ● Initiated
Buy 2025-12-09 40% win rate (5 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-05-28 31% win rate (48 calls)
Benchmark ● Initiated
Buy 2025-04-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →